Back pain, one of the most prevalent medical conditions, is most often due to degeneration of the spinal disc. To date, no therapy exists that can regenerate nucleus tissue or reverse or heal damaged discs, leaving surgical intervention as the only option. In the United States alone, more than 400,000 lumbar discectomies and 500,000 spinal fusions are performed each year. Neither procedure addresses the underlying conditions that lead to irreversible disc degeneration. Both procedures also have significant drawbacks, such as restricted mobility and continued degeneration of the affected and/or adjacent discs.
Using NuQu to restore a damaged disc could save the disc and prevent further degeneration. NuQu is composed of culture-expanded juvenile cartilage cells in a protein-based carrier. These cells have been proved to have far greater regenerative potential than adult cartilage cells (1).
NuQu is an early-stage development cell-based therapy aimed at resolving the cause of back pain associated with degenerative disc disease. This pioneering cell therapy, under development by ISTO, shows promise in restoring degenerated disc structure and disc height in preclinical studies.
1. Adkisson HD IV, Gillis MP, Davis EC, et al. In vitro generation of scaffold independent neocartilage. Clin Orthop Rel Res 2001; 391S:S280-S294.